Clinical outcomes in Fabry patients switching to agalsidase beta for renal ineffectiveness of the primary Fabry therapy: a single-centre analysis
Treatment switch from agalsidase alfa or migalastat to agalsidase beta can attenuate eGFR decline and enhance lyso-Gb3 reduction, confirming the dose-dependent effect of agalsidase beta to further slow down FD progression.
Authors
- Eleonora Riccio (ORCID: https://orcid.org/0000-0002-5379-1104)
- Guido Iaccarino (ORCID: https://orcid.org/0000-0002-8997-835X)
- Pasquale Buonanno (ORCID: https://orcid.org/0000-0001-7933-6209)
- Ivana Capuano (ORCID: https://orcid.org/0000-0002-6559-196X)
- Federico Pieruzzi (ORCID: https://orcid.org/0000-0002-1302-6846)
- Antonio Pisani (ORCID: https://orcid.org/0000-0003-0241-8323)
- Renzo Mignani (ORCID: https://orcid.org/0000-0001-8507-8939)
- Calogero Lino Cirami (ORCID: https://orcid.org/0000-0002-3776-4691)
Institutions
- IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola (IT)
- Azienda Ospedaliera San Gerardo (IT)
- Azienda Ospedaliero-Universitaria Careggi (IT)
- Federico II University Hospital (IT)
- University of Milano-Bicocca (IT)
- University of Naples Federico II (IT)
- University of Bologna (IT)
Publication Details
- Journal
- Clinical Kidney Journal
- Published
- 2025-10-14
- DOI
- https://doi.org/10.1093/ckj/sfaf318
- Primary Topic
- Lysosomal Storage Disorders Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00